Sagimet Biosciences Inc. - Seri (SGMT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.27
- Surprise
- —
- Score today
- 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29 — benzinga, 2026-08-14
- Sagimet Biosciences Says FDA Cleared IND And Issued Study May Proceed Letter For Phase 3 Trial Of Denifanstat In Moderat — benzinga, 2026-08-13
- Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56 — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates SGMT Sell at 5.7/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate. Next scheduled report: 2027-03-11.
What argues against it
- Concentration risk — Pipeline: denifanstat
- Quality below floor (1.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.13
- Price target
- $23.73
- Stop
- $9.42
- Upside to target
- +134.3%
- Reward-to-risk
- 9.8:1
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
SGMT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $735.2M
- P/E (fwd)
- -7.0
- 52-week range
- $4.50–$11.45
- Off 52-week high
- 11.5%
- RSI (14)
- 48
- Volume vs avg
- 0.93×
- Score today
- 5.7/10